Coverage of new sickle cell gene therapy treatments in US state Medicaid programs is likely to lag due to the treatment’s big initial sticker shock to the state health insurance systems and the unique policy determinations that states must make to execute coverage of drugs that can only be given in limited locations nationwide and must be coupled with other high-cost medical care.
Medicaid is estimated to account for about 50% of the 100,000 sickle cell disease patients in the US, and the...







